Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10643418 | 0.88 | OPRM1 (0.44) | OPRM1SPHK1LMNADNM1TSHR | |
| SCHEMBL9562613 | 0.81 | OPRM1 (0.42) | OPRM1SPHK1LMNADNM1TSHR | |
| SCHEMBL18697945 | 0.80 | OPRM1 (0.46) | OPRM1SPHK1LMNADNM1TSHR | |
| SCHEMBL25517663 | 0.80 | OPRM1 (0.46) | OPRM1SPHK1LMNADNM1TSHR | |
| SCHEMBL11284637 | 0.80 | OPRM1 (0.46) | OPRM1SPHK1LMNADNM1TSHR | |
| SCHEMBL276746 | 0.79 | — | — | |
| SCHEMBL10657571 | 0.79 | OPRM1 (0.55) | OPRM1SPHK1LMNADNM1TSHR | |
| SCHEMBL31169240 | 0.79 | OPRM1 (0.55) | OPRM1SPHK1LMNADNM1TSHR | |
| SCHEMBL11486416 | 0.79 | OPRM1 (0.55) | OPRM1SPHK1LMNADNM1TSHR | |
| SCHEMBL13858988 | 0.79 | OPRM1 (0.55) | OPRM1SPHK1LMNADNM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233167-B2 | 14-hydroxy-docosahexaenoic acid compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170349560-A1 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233167-B2 | 14-hydroxy-docosahexaenoic acid compounds | FASN, ALOX5, FADS2 | OPRM1 2737/4885SPHK1 357/4885LMNA 824/4885 |
| US-20170349560-A1 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS | FASN, FADS2, ALOX15 | OPRM1 2577/4885SPHK1 370/4885LMNA 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.